Navigation Links
Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
Date:5/10/2011

ROCKVILLE, Md., May 10, 2011 /PRNewswire/ --Neuralstem, Inc. (NYSEAmex: CUR)  reported its financial results for the three months period ended March 31, 2011 and provided a business and clinical update.  

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

"The Company reached several major milestones in the first Quarter of 2011.  Interim data from our Phase I trial for ALS was presented at the American Academy of Neurology Annual Meeting in April, where the principal investigator of the trial, Dr. Eva Feldman, reported the ground-breaking work was both feasible and safe," said Neuralstem's Chairman and Chief Scientific Officer Karl Johe, PhD. "We completed all of the transplantations for the first 12-patient cohort in our ALS trial in mid-April. Also, in February, the U.S. FDA Office of Orphan Products Development granted the Company orphan drug designation for the cell therapy treatment of ALS with its human spinal cord-derived neural stem cells (NSI-566RSC)."

"Further, after receiving approval from the FDA late in 2010 for our first small molecule drug  trial, NSI-189 for major depression, we began dosing in our phase 1a patients in February," said Dr. Johe. "Looking forward, we expect the FDA to approve the second part of the Phase I ALS trial this summer. The next group of patients will receive injections in the upper spinal cord area, where we believe that the injections can ultimately aid in the preservation of respiratory capacity for ALS patients. Additionally, we expect the NSI-189 major depression trial to proceed to Phase Ib with escalating dosing of depressed patients this summer.  The small molecule program has been strengthened by the addition of Maurizio Fava, MD, Director of the Massachusetts General Hospital Department of Psychiatry Clinical Trials Network and Institute, who is now consulting on the trial des
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
2. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
3. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
4. Neuralstem Completes $5.25 Million Financing
5. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
6. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
8. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
9. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
10. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
11. Neuralstem Reports Second Quarter Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 Whitehouse Laboratories has formally ... Stability Testing and Package Test Capacity. Responding to growing ... a dramatic increase in environmental chamber storage space that ... and aging samples to be securely held on site ... capital expenditure has already taken place with the recent ...
(Date:10/30/2014)... , Oct. 30, 2014 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... 8:30 a.m. ET in Boston, MA. ... available on the "Investors & Media" section of the Company,s ... the Isis website within 48 hours and will be archived ...
(Date:10/30/2014)... of the key challenges in the development of quantum ... , In a paper published today (28 October) in ... show how to make a new type of flexibly ... such as high-precision sensors and specialised superfast computers, often ... the methods for trapping these tiny particles are hugely ...
(Date:10/27/2014)... The new research report, “Gas ... Medium), Sub-type (Primary & Secondary), and End-User (Transmission ... & Power Generation) - Trends and Forecasts to ... analysis and forecasting of the market size. , ... 52 Figures spread through 146 Pages and in-depth ...
Breaking Biology Technology:Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... MYL ),today announced that Mylan Pharmaceuticals Inc. has ... (FDA) for its Abbreviated New,Drug Application (ANDA) for Ropinirole ... (base), 2 mg (base), 3 mg (base), 4 mg ... the generic version of,GlaxoSmithKline,s Requip(R) Tablets, which had total ...
... Mammography Revenue Growth and FDA Approval of Fujifilm CAD,Product Expected to Drive Growth ... ... Conference ... iCAD, Inc. (Nasdaq:,ICAD), an industry-leading provider of Computer-Aided Detection (CAD),solutions for the early ...
... Increased 50.7% to $38.8 Million in 1Q08 -- ... -- 1Q08 Diluted EPS $0.12 versus 1Q07 Diluted EPS $.10 on ... ... (NYSE: AOB ), a pharmaceutical company dedicated to,improving health through the development, ...
Cached Biology Technology:iCAD Reports First Quarter 2008 Financial Results 2iCAD Reports First Quarter 2008 Financial Results 3iCAD Reports First Quarter 2008 Financial Results 4iCAD Reports First Quarter 2008 Financial Results 5iCAD Reports First Quarter 2008 Financial Results 6iCAD Reports First Quarter 2008 Financial Results 7iCAD Reports First Quarter 2008 Financial Results 8iCAD Reports First Quarter 2008 Financial Results 9American Oriental Bioengineering Reports First Quarter 2008 Financial Results 2American Oriental Bioengineering Reports First Quarter 2008 Financial Results 3American Oriental Bioengineering Reports First Quarter 2008 Financial Results 4American Oriental Bioengineering Reports First Quarter 2008 Financial Results 5American Oriental Bioengineering Reports First Quarter 2008 Financial Results 6American Oriental Bioengineering Reports First Quarter 2008 Financial Results 7American Oriental Bioengineering Reports First Quarter 2008 Financial Results 8
(Date:10/30/2014)... or reverse soil subsidence and reduce greenhouse gas ... River Delta by Dartmouth College researchers and their ... the first to continually measure the fluctuations of ... wetlands, appears in the journal by ... drainage of organic soils has resulted in vast ...
(Date:10/30/2014)... LANSING, Mich. – When most animals begin life, cells ... or a vital organ. However, mammals, including humans, are ... a different first choice – to become the protective ... It,s during this critical first step that research from ... published in the current issue of PLOS ...
(Date:10/30/2014)... therapeutics present unique challenges when it comes to ... harm. New consensus guidelines for toxicity testing that ... characteristics of these novel biopharmaceuticals are presented in ... from Mary Ann Liebert, Inc. publishers . ... Nucleic Acid Therapeutics website until November 30, ...
Breaking Biology News(10 mins):Dartmouth study finds restoring wetlands can lessen soil sinkage, greenhouse gas emissions 2Identifying the source of stem cells 2New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2
... Since its discovery in the 18th century, cocaine has ... reward centres in low doses, cocaine is extremely addictive ... potent compound did not evolve to ensnare humans in ... cocaine is a powerful insect neurotoxin, protecting coca bushes ...
... WA This Christmas season, think twice about spending ... tree. The good, old-fashioned methodkeeping your tree in a ... keep your tree green and healthy. Researchers have determined ... trees; in fact, in several cases the chemical retardants ...
... LANSING, Mich. Diversity is valuable socially, economically and ... has found that growing more corn to produce ethanol ... of beneficial insects to control pests, a loss valued ... states studied (Michigan, Iowa, Minnesota and Wisconsin). "Corn ...
Cached Biology News:Honeybees succumb to cocaine's allure 2Flame retardants prove ineffective on fresh-cut Christmas trees 2Diverse landscapes are better: Policymakers urged to think broadly about biofuel crops 2
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
Mouse polyclonal antibody raised against a partial recombinant CD320. NCBI Entrez Gene ID = 51293...
Mouse monoclonal antibody raised against a partial recombinant CHD8. NCBI Entrez Gene ID = CHD8...
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Biology Products: